Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
42
NWBO Quote, Financials, Valuation and Earnings
Last price:
$0.25
Seasonality move
:
24.69%
Day range:
$0.24 - $0.26
52-week range:
$0.17 - $0.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
376.36x
P/B ratio:
--
Volume:
2.1M
Avg. volume:
3.1M
1-year change:
-1.84%
Market cap:
$389.6M
Revenue:
$1.4M
EPS (TTM):
-$0.07
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Northwest Biotherapeutics, Inc. has 3063.31% upside to fair value with a price target of -- per share.
NWBO vs. S&P 500
-
Over the past 5 trading days, Northwest Biotherapeutics, Inc. has overperformed the S&P 500 by 7.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Northwest Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Northwest Biotherapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Northwest Biotherapeutics, Inc. reported revenues of $200K.
Earnings Growth
-
Northwest Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Northwest Biotherapeutics, Inc. reported earnings per share of -$0.02.
Enterprise value:
475.5M
EV / Invested capital:
--
Price / LTM sales:
376.36x
EV / EBIT:
--
EV / Revenue:
507.50x
PEG ratio (5yr expected):
-0.93x
EV / Free cash flow:
-9.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.1M
Return On Assets:
-311.49%
Net Income Margin (TTM):
-9580.9%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-7160%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.1M | $1.6M | $937K | $357K | $200K | |
| Gross Profit | $342K | -$368K | -$1.1M | -$165K | -$321K | |
| Operating Income | -$58.5M | -$63.2M | -$64.9M | -$14.8M | -$14.3M | |
| EBITDA | -$56.8M | -$61.2M | -$62.9M | -$14.3M | -$13.8M | |
| Diluted EPS | -$0.07 | -$0.06 | -$0.07 | -$0.02 | -$0.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.3M | $11.8M | $8.5M | $5.2M | $7.2M | |
| Total Assets | $28.3M | $31.2M | $31.6M | $29.4M | $30.7M | |
| Current Liabilities | $312.3M | $116.1M | $49.2M | $59.6M | $87.9M | |
| Total Liabilities | $330M | $126.2M | $68.9M | $93.6M | $125.9M | |
| Total Equity | -$301.7M | -$95M | -$37.4M | -$64.2M | -$95.2M | |
| Total Debt | $26M | $30.1M | $23.4M | $36.9M | $49.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$45.5M | -$53.8M | -$50.2M | -$8.2M | -$13.9M | |
| Cash From Investing | -$5.2M | -$1.4M | -$988K | -$176K | -$513K | |
| Cash From Financing | $49.7M | $55.3M | $51.7M | $11.6M | $11.6M | |
| Free Cash Flow | -$50.7M | -$55.1M | -$50.9M | -$8.4M | -$14.1M | |
NWBO
Sector
Market Cap
$389.6M
$27.9M
Price % of 52-Week High
52.82%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-7.09%
-1.49%
1-Year Price Total Return
-1.84%
-16.66%
Beta (5-Year)
-0.840
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.24
200-day SMA
Sell
Level
$0.25
Bollinger Bands (100)
Sell
Level
0.24 - 0.26
Chaikin Money Flow
Sell
Level
-462.8M
20-day SMA
Buy
Level
$0.24
Relative Strength Index (RSI14)
Buy
Level
57.39
ADX Line
Buy
Level
9.89
Williams %R
Neutral
Level
-20.0573
50-day SMA
Buy
Level
$0.24
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-322.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-84.2372)
Sell
CA Score
(Annual)
Level (-24.2496)
Buy
Beneish M-Score
(Annual)
Level (-9.4807)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (36.1326)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
Stock Forecast FAQ
In the current month, NWBO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NWBO average analyst price target in the past 3 months is --.
-
Where Will Northwest Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Northwest Biotherapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Northwest Biotherapeutics, Inc.?
Analysts are divided on their view about Northwest Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Northwest Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Northwest Biotherapeutics, Inc.'s Price Target?
The price target for Northwest Biotherapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NWBO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Northwest Biotherapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NWBO?
You can purchase shares of Northwest Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Northwest Biotherapeutics, Inc. shares.
-
What Is The Northwest Biotherapeutics, Inc. Share Price Today?
Northwest Biotherapeutics, Inc. was last trading at $0.25 per share. This represents the most recent stock quote for Northwest Biotherapeutics, Inc.. Yesterday, Northwest Biotherapeutics, Inc. closed at $0.25 per share.
-
How To Buy Northwest Biotherapeutics, Inc. Stock Online?
In order to purchase Northwest Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NWBO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NWBO
Sector
P/E ratio
--
23.85x
PEG ratio
-0.93x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
376.36x
1.58x
Growth Metrics
NWBO
Sector
Revenue growth
-43.98%
4.62%
Earnings growth
-17.42%
10.5%
Revenue (5-year growth)
-10.53%
6.5%
Earnings forecast
--
-$0.21
Profitability
NWBO
Sector
Profitability FY 2024
-$662K
$3.6M
Return on invested capital
--
-31.87%
Return on assets
-311.49%
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
17
Next Earnings Date
Mar
3
Estimated Next Earnings Date
Feb
16
Balance Sheet
NWBO
Sector
Total cash
$4.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$26.8M
$76.9M
Long term debt
$49.8M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
